



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of) Examiner: L. R. HELMS
V. Hsei) Group Art Unit of the Parent Application:
For: **ANTIBODY FRAGMENT-) 1642**
POLYMER CONJUGATES AND) Customer No.: 25213
USES OF SAME)
Serial No.: 09/489,394)
Filed: January 21, 2000)
Atty. Docket No.: Genent .092A)

Express Mail Label No.: EV 194295511 US
Mailed in Menlo Park, CA on: January 30, 2003

BOX RCE
Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

Preliminary Amendment

Dear Sir:

The present Preliminary Amendment is filed concurrently with the filing of a Request for Continued Examination (RCE). Before issuing an Office Action, please enter the following amendments, and consider the following remarks:

In the Claims:

Please cancel claims 1-7, 9-11, 13, 15, 16, 18-24, and 26-37, without prejudice.

Please add the following new claims:

124
38. (New)

A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein (a) the apparent molecular weight of the conjugate, as determined by size exclusion chromatography, is at least about 500 kD, and (b) the average actual molecular weight of each nonproteinaceous polymer molecule is at least 20 kD, and wherein the antibody fragment comprises an antigen binding site for a polypeptide selected from the group consisting of: human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human Apo-2 receptor, human tumor necrosis factor- α (TNF- α), human tissue factor (TF), human

H
191E

16
3-1/123

rule
124
E1

124